MINIRIN
Clinical safety rating
cautionComprehensive clinical and safety monograph for MINIRIN (MINIRIN).
Comprehensive clinical and safety monograph for MINIRIN (MINIRIN).
Central diabetes insipidusNocturnal enuresisHemophilia A with factor VIII levels >5%von Willebrand disease (type I)
Headache Nausea Stomach pain
Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.
| Metabolism | Primarily metabolized in the liver; CYP450 enzymes not significantly involved. |
| Excretion | Renal (primarily as unchanged drug via glomerular filtration and tubular secretion; ~65% of an intravenous dose excreted unchanged in urine within 24 hours); fecal (~5–10% of an oral dose); minimal biliary elimination. |
| Half-life | Terminal elimination half-life: 2–3 hours (intravenous, subcutaneous); 3–5 hours (oral). Clinical context: Short half-life necessitates frequent dosing; duration of antidiuretic effect may outlast plasma levels due to receptor binding. |
| Protein binding | Approximately 1% bound to plasma proteins (negligible binding; primarily to albumin). |
| Volume of Distribution | 0.2–0.3 L/kg. Clinical meaning: Low Vd indicates limited extravascular distribution; mostly confined to extracellular fluid. |
| Bioavailability | Oral: 0.1–0.5% (low due to enzymatic degradation in GI tract and extensive first-pass metabolism); Subcutaneous: ~85–90%; Intranasal: ~3–5% (variable due to nasal absorption and metabolism). |
| Onset of Action | Intravenous: 15–30 minutes; Subcutaneous: 30–60 minutes; Oral: 1–2 hours; Intranasal: 30–60 minutes. Onset refers to initial antidiuretic effect. |
| Duration of Action | Intravenous: 6–12 hours; Subcutaneous: 6–12 hours; Oral: 6–12 hours; Intranasal: 8–12 hours. Clinical notes: Duration is dose-dependent; in central diabetes insipidus, dosing interval typically 8–12 hours. |
| Molecular Weight | 1069.2 |
Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.
| Dosage form | SPRAY, METERED |
| Renal impairment | GFR >50 mL/min: No adjustment. GFR 10-50 mL/min: Caution, reduce dose by 50% or extend interval. GFR <10 mL/min: Contraindicated or avoid use. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use. |
| Pediatric use | Intranasal: Infants and children, 5 mcg (0.5 spray) once daily, titrate to effect. Oral: 0.05-0.1 mg three times daily, weight-based (0.1-1 mcg/kg) but not established. |
| Geriatric use | Initiate at lowest effective dose; monitor for hyponatremia and fluid retention; adjust based on renal function. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at therapeutic doses. Use only if clearly needed. |
| 2nd trimester | May be used for diabetes insipidus and nocturnal enuresis if benefits outweigh risks. Monitor for hyponatremia. |
| 3rd trimester | May cause uterine contractions at high doses; avoid for preterm labor. Safe for diabetes insipidus at low doses. |
Clinical note
Comprehensive clinical and safety monograph for MINIRIN (MINIRIN).
| Placental transfer | Crosses placenta minimally; limited data suggest low transfer. |
| Breastfeeding | Minimally excreted into breast milk; unlikely to cause adverse effects in infants. Use with caution, monitor infant for hyponatremia. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Desmopressin (MINIRIN) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. In humans, limited data show no increased risk of major birth defects. However, due to antidiuretic effects, monitor for hyponatremia and fluid overload during pregnancy, particularly in third trimester when plasma volume increases. |
| Fetal Monitoring | Monitor maternal serum sodium, urine output, and fluid balance to prevent hyponatremia and water intoxication. In late pregnancy and postpartum, monitor for uterine contractions due to possible vasopressin activity. Fetal monitoring should include heart rate and growth if prolonged use. |
| Fertility Effects | In clinical studies, desmopressin has not been shown to impair fertility. No adverse effects on reproductive function in males or females have been reported. However, any hormone imbalance from underlying condition (e.g., diabetes insipidus) may affect fertility. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Headache Nausea Stomach pain |
| Serious Effects |
Hypersensitivity to desmopressin or any componentHyponatremiaPsychogenic polydipsiaModerate to severe renal impairment (CrCl <50 mL/min)
| Precautions | Fluid restriction required to prevent water intoxication and hyponatremia, Monitor serum sodium in at-risk patients (e.g., elderly, cystic fibrosis), Use with caution in patients with hypertension, coronary artery disease, or renal impairment, Allergic reactions possible |
| Food/Dietary | Avoid excessive fluid intake, especially water, within 1 hour before and after dosing. Limit foods with high water content (e.g., soups, melons). No specific food-drug interactions; focus on fluid restriction to prevent hyponatremia. |
| Clinical Pearls | Desmopressin (Minirin) is a synthetic analog of vasopressin; avoid use in patients with hyponatremia or impaired renal function. Monitor sodium levels especially in elderly and young children. Intranasal absorption may be variable with nasal congestion; consider using oral or injectable forms in such cases. For nocturnal enuresis, restrict fluids 1 hour before dose to reduce hyponatremia risk. |
| Patient Advice | Do not drink more than 250 mL (8 oz) of fluids within 1 hour before or after taking Minirin to prevent water intoxication. · For intranasal spray, prime pump before first use or if not used for >1 week. Blow nose gently before administration. · Take exactly as prescribed; do not increase dose without consulting your doctor. · Report signs of hyponatremia: headache, nausea, vomiting, confusion, seizures, or unusual fatigue. · If using for bedwetting, take at bedtime and ensure voiding just before sleep. |
Loading safety data…